Methods and Compositions For Modulating Angiogenesis

• US 20100247540A1
• Filed: 07/20/2009
• Published: 09/30/2010
• Est. Priority Date: 10/30/2003
• Status: Abandoned Application

• Current Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Original Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Inventors: Wang, Yu, Burns, Jennifer, Summers, Bretton, Miao, Zhenhua, Schall, Thomas, Howard, Maureen
• Application Number:
  US12/506,199
• Publication Number:
  US 20100247540A1
• Time in Patent Office: Days
• US Class Current: 424/139.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

The present invention provides method and compositions for modulating angiogenesis.

Claims

1. A method of modulating angiogenesis in a subject, the method comprising administering to the subject an antibody that binds to a CCX-CKR2 polypeptide and competes with SDF-1 or I-TAC for binding to the CCX-CKR2 polypeptide.

2. The method of claim 1, wherein the subject has arthritis, thereby ameliorating the arthritis.

3. The method of claim 2, wherein the agent is administered in combination with a second agent that inhibits angiogenesis.

4. The method of claim 1, wherein the subject has a wound, fracture or burn and the antibody is administered to the wound, fracture, or burn, thereby enhancing healing of the wound, fracture, or burn.

5. The method of claim 4, wherein the agent is administered in combination with a second agent that promotes angiogenesis.

6. The method of claim 1, wherein the subject is a human.